Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-2002
- Development stage
- Phase 1
- Lead developer
- Hengrui Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SHR-2002 is a bispecific antibody drug candidate developed for the treatment of advanced solid tumors and other malignant neoplasms. It acts as an immune checkpoint inhibitor targeting both the CD112 receptor (CD112R, also known as PVRIG) and TIGIT protein, modulating immunoglobulin pathways to enhance anti-tumor immune responses. The drug is administered intravenously and has been evaluated in monotherapy and in combination with other anti-cancer agents such as SHR-1316 (an anti-PD-L1 antibody). Clinical trials have reached Phase II for solid tumors, with studies conducted primarily in Australia and China. The primary developers are Jiangsu Hengrui Medicine Co., Atridia, and Suzhou Suncadia Biopharmaceuticals[1][2][3][5].
02
Targets
PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)TIGIT (T cell immunoreceptor with Ig and ITIM domains)IgA (Immunoglobulin A)
Beyond the preview
Go deeper on SHR-2002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-2002.